CU23236A1 - PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P - Google Patents

PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P

Info

Publication number
CU23236A1
CU23236A1 CU2002008620030286A CU20030286A CU23236A1 CU 23236 A1 CU23236 A1 CU 23236A1 CU 2002008620030286 A CU2002008620030286 A CU 2002008620030286A CU 20030286 A CU20030286 A CU 20030286A CU 23236 A1 CU23236 A1 CU 23236A1
Authority
CU
Cuba
Prior art keywords
cea
human
formulations
chain
scfv
Prior art date
Application number
CU2002008620030286A
Other languages
English (en)
Inventor
Negrin Yasser Perera
Feyt Rolando Pajon
Nieto Gerardo Enrique Guillen
Garcia Gretel Sardinas
Nunez Lazaro Hiram Betancourt
Serra Lila Rosa Castellanos
Diaz Darien Garcia
Perez Olivia Niebla
Menendez Evelin Caballero
Blanco Isaac Gonzalez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU2002008620030286A priority Critical patent/CU23236A1/es
Priority to ARP040104482A priority patent/AR046937A1/es
Priority to BRPI0417334-1A priority patent/BRPI0417334A/pt
Priority to AU2004294377A priority patent/AU2004294377A1/en
Priority to PCT/CU2004/000016 priority patent/WO2005054282A1/es
Priority to CA002547537A priority patent/CA2547537A1/en
Priority to CNB2004800358798A priority patent/CN100549027C/zh
Priority to EP04802608A priority patent/EP1693379B1/en
Priority to AT04802608T priority patent/ATE456573T1/de
Priority to KR1020067011597A priority patent/KR20060124625A/ko
Priority to US10/580,888 priority patent/US20070128230A1/en
Priority to RU2006123414/13A priority patent/RU2335505C2/ru
Priority to NZ547521A priority patent/NZ547521A/xx
Priority to DE602004025377T priority patent/DE602004025377D1/de
Priority to ZA200604492A priority patent/ZA200604492B/en
Priority to NO20063017A priority patent/NO20063017L/no
Publication of CU23236A1 publication Critical patent/CU23236A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion se refiere a fragmentos de anticuerpoUso de un nuevo antígeno vacunal aplicado de manera preventiva o terapÉutica contra enfermedades bacs tipo Fv de cadena sencilla (scFv) mono y divalente (diacuerpo), obtenidos por tÉcnicas de ADN recoterianas, virales, cancerosas, o de otro origen. Embinante y con secuencias aminoacídicas no reportal objetivo tÉcnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro pdas antes en sus dominios variables de cadena pesarotector de las vacunas ya existentes y extenderloda (VH) y ligera (VL). Estos fragmentos scFv monovalente y diacuerpo exhiben altas afinidades por el contra diferentes patogenos. Para lograr este objetivo se aislo e identifico la proteína NMB0928 co CEA humano [(0.5+/- 0.4) x 10(9) L mol -1 y (2.8+/- 0.3) x 10 (10) L mol -1, respectivamente] y recmo componente de las preparaciones de membrana extonocen un epítope dependiente de la conservacion derna de Neisseria meningitidis, capaz de inducir ae los carbohidratos. Estos dos fragmentos no presectividad bactericida. Adicionalmente, se clono y expreso el gen codificante para la proteína NMB0928ntan reactividad cruzada con cÉlulas y tejidos humanos normales, excepto la mucosa clonica normal do, la cual se purifico evaluAndose luego se inmunogenicidad en biomodelos animales. El secuenciamientnde el CEA estA ocasinalmente presente. Los fragmentos pueden producirse mediante la expresion en mio de genes homologos evidencio, por su elevado gracroorganismos recombinantes, a partir del clonaje do de conservacion, su alto valor como antígeno inde secuencias de Acidos nucleicos codificantes parductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. Las formulaciones ra regiones variables obtenidas del hibridoma que produce el AcM CB/ior-CEA.1. El scFv monovalente y esultantes de esta invencion son aplicables en la industria farmacÉutica como formulaciones vacUnaleel diacuerpo tienen la capacidad de identificar in vivo a cÉlulas productoras de CEA humano que crecs para uso humano. en formando tumores en ratones. El scFv monovalente y el diacuerpo tienen un tamano molecular 5 y 2.5 veces inferior, respectivamente, que un anticuerpo completo y no poseen dominios Fc, lo que les confiere el potencial de penentrar mejor los tejidos in vivo y de ser menos inmunogÉnicos en el hombre, por lo que poseen ventajas perspectivas para el desarrollo de formulaciones para el diagnostico por imAgenes y el tratamiento de tumores humanos que expresan CEA, ademAs de en otros usos diagnosticos in vitro.
CU2002008620030286A 2003-12-03 2003-12-03 PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P CU23236A1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CU2002008620030286A CU23236A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
ARP040104482A AR046937A1 (es) 2003-12-03 2004-12-01 Proteina nmb0928 y su uso en formulaciones farmaceuticas
BRPI0417334-1A BRPI0417334A (pt) 2003-12-03 2004-12-02 proteìna nmb0928 e uso da mesma em formulações farmacêuticas
AU2004294377A AU2004294377A1 (en) 2003-12-03 2004-12-02 Protein NMB0928 and use thereof in pharmaceutical formulations
PCT/CU2004/000016 WO2005054282A1 (es) 2003-12-03 2004-12-02 Proteína nmb0928 y su uso en formulaciones farmaceuticas
CA002547537A CA2547537A1 (en) 2003-12-03 2004-12-02 Protein nmb0928 and use thereof in pharmaceutical formulations
CNB2004800358798A CN100549027C (zh) 2003-12-03 2004-12-02 Nmb0928蛋白及其在药物制剂中的用途
EP04802608A EP1693379B1 (en) 2003-12-03 2004-12-02 Protein nmb0928 and use thereof in pharmaceutical formulations
AT04802608T ATE456573T1 (de) 2003-12-03 2004-12-02 Nmb0928-protein und dessen verwendung in pharmazeutischen formulierungen
KR1020067011597A KR20060124625A (ko) 2003-12-03 2004-12-02 단백질 ｎｍｂ0928 및 약학적 제형에서의 이의 용도
US10/580,888 US20070128230A1 (en) 2003-12-03 2004-12-02 Protein nmb0928 and use thereof in pharmaceutical formulations
RU2006123414/13A RU2335505C2 (ru) 2003-12-03 2004-12-02 Белок nmb0928 и его применение в фармацевтических композициях
NZ547521A NZ547521A (en) 2003-12-03 2004-12-02 Protein NMB0928 and use thereof in pharmaceutical formulations
DE602004025377T DE602004025377D1 (de) 2003-12-03 2004-12-02 Nmb0928-protein und dessen verwendung in pharmazeutischen formulierungen
ZA200604492A ZA200604492B (en) 2003-12-03 2006-06-01 Protein NMB0928 and use thereof in pharmaceutical formulations
NO20063017A NO20063017L (no) 2003-12-03 2006-06-28 Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2002008620030286A CU23236A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P

Publications (1)

Publication Number Publication Date
CU23236A1 true CU23236A1 (es) 2007-09-26

Family

ID=40091627

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2002008620030286A CU23236A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P

Country Status (16)

Country Link
US (1) US20070128230A1 (es)
EP (1) EP1693379B1 (es)
KR (1) KR20060124625A (es)
CN (1) CN100549027C (es)
AR (1) AR046937A1 (es)
AT (1) ATE456573T1 (es)
AU (1) AU2004294377A1 (es)
BR (1) BRPI0417334A (es)
CA (1) CA2547537A1 (es)
CU (1) CU23236A1 (es)
DE (1) DE602004025377D1 (es)
NO (1) NO20063017L (es)
NZ (1) NZ547521A (es)
RU (1) RU2335505C2 (es)
WO (1) WO2005054282A1 (es)
ZA (1) ZA200604492B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
CU23575A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Vaccines US Inc. Neisseria meningitidis vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4219821A1 (de) * 1992-06-17 1993-12-23 Boehringer Mannheim Gmbh Spezifischer Nachweis von Neisseria Gonorrhoeae
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
CN100379757C (zh) * 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9911692D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic combinations
PT2275551E (pt) * 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens

Also Published As

Publication number Publication date
NO20063017L (no) 2006-09-01
ATE456573T1 (de) 2010-02-15
RU2006123414A (ru) 2008-01-10
WO2005054282A1 (es) 2005-06-16
BRPI0417334A (pt) 2007-03-27
CN100549027C (zh) 2009-10-14
RU2335505C2 (ru) 2008-10-10
AU2004294377A1 (en) 2005-06-16
NZ547521A (en) 2009-07-31
US20070128230A1 (en) 2007-06-07
CN1890261A (zh) 2007-01-03
AR046937A1 (es) 2006-01-04
EP1693379A1 (en) 2006-08-23
ZA200604492B (en) 2007-05-30
KR20060124625A (ko) 2006-12-05
EP1693379B1 (en) 2010-01-27
CA2547537A1 (en) 2005-06-16
DE602004025377D1 (de) 2010-03-18

Similar Documents

Publication Publication Date Title
KR102833333B1 (ko) 치료적 항암 네오에피토프 백신
ES2609925T3 (es) Proteínas de fusión con LLO no hemolítica y métodos para utilizar las mismas
UA126380C2 (uk) Генно-інженерний вірус вісповакцини
ES2520026T3 (es) Composiciones y métodos para potenciar respuestas inmunitarias
ES2585702T3 (es) Composiciones y métodos para la unión al ácido lisofosfatídico
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
ES2688883T3 (es) Fragmentos mutantes de OspA y métodos y usos relacionados con los mismos
JP2019511222A5 (es)
ES2398492T3 (es) Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
MX2010006148A (es) Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos.
DOP2012000066A (es) Moleculas anticuerpo anti-gcc y composiciones y metodos relacionados
CN120939216A (zh) 抗hpv和hpv相关的疾病的新疫苗
AR082892A1 (es) Dominios variables individuales de inmunoglobulina de union al factor de crecimiento endotelial vascular (vegf)
WO2008129103A1 (es) Empleo de la hemaglutinina del virus de la peste porcina africana como adyuvante
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
CN115944722B (zh) 一种抗肿瘤mRNA疫苗及其制备方法和应用
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
AR127743A1 (es) Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
CN108770343A (zh) 用于治疗癌症的使用MICA/Bα3结构域的疫苗接种
CN111295200B (zh) 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
CU23236A1 (es) PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
CN103352047B (zh) 旋毛虫肌幼虫es抗原基因疫苗及其制备方法
Chen et al. DNA-scaffolded multivalent vaccine against SARS-CoV-2
MX2024011785A (es) Peptidos antigenicos para la prevencion y el tratamiento del cancer
US20150209422A1 (en) Immunization with rabies virus vector expressing foreign protein antigen